Nutra Pharma Corp (NPHC) 0.0109 $NPHC
Nutra Pharma Letter to Shareholders
Marketwired - Wed Dec 30, 7:30AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview
Marketwired - Wed Dec 16, 7:30AM CST
QualityStocks today announces the availability of a new audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTCQB: NPHC), a biotech company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The interview can be heard at http://www.QualityStocks.net/interview-nphc.php.
Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite
Marketwired - Mon Dec 14, 7:30AM CST
Nutra Pharma Corp. (the "Company"
(OTCQB: NPHC), a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases, today announces that it has engaged the Corporate Communications Services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value over the past 9 years and 11 months.
Nutra Pharma files for additional orphan drug application with the US FDA for RPI-78M for Myasthenia Gravis
M2 - Thu Dec 10, 5:02AM CST
Biotechnology company Nutra Pharma Corporation (OTCQB:NPHC) disclosed on Wednesday that it has applied for an additional potential orphan drug designation with the US-FDA for its RPI-78M drug candidate for the treatment of Myasthenia Gravis (MG) through the modulation of the immune system, preventing autoimmune effects.
Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis
Marketwired - Wed Dec 09, 8:02AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, as well as developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have applied for an Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Myasthenia Gravis (MG). On September 8, 2015, the Company announced that they had been granted an Orphan Designation for the treatment of Pediatric Multiple Sclerosis. The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
StockNewsNow.com Publishes New SNNLive Video Interview With Nutra Pharma Corporation
Marketwired - Tue Oct 27, 7:31AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Rik J. Deitsch, CEO of Nutra Pharma Corporation (OTC: NPHC), operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, (see here: www.NutraPharma.com). The video interview was recorded on Wednesday, October 14th, 2015 On-Location in Florida.
Nutra Pharma to Present at Upcoming Investment Conference
Marketwired - Wed Sep 09, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, will be presenting at the upcoming See Thru Equities Conference being held at the Convene Grand Central in New York City on Thursday, September 10th. The presentation will be made by the Company's CEO, Rik J Deitsch, who will be providing updates on the sales and marketing activities for the Company's over-the-counter (OTC) pain relievers, Nyloxin(R) and Pet Pain-Away, as well as discussing the Company's drug product pipeline. This will include a presentation on the designation of Orphan Drug Status for RPI-78M in the treatment of juvenile Multiple Sclerosis (MS).
Nutra Pharma wins US FDA's orphan drug status for RPI-78M for treating juvenile multiple sclerosis
M2 - Wed Sep 09, 3:27AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) reported on Tuesday ththat it has been given orphan drug designation from the US-FDA for its RPI-78M drug candidate for treating multiple sclerosis in children.
Nutra Pharma's RPI-78M Granted Orphan Drug Status by the US Food and Drug Administration for the Treatment of Juvenile Multiple Sclerosis
Marketwired - Tue Sep 08, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC) announced today that they have received Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children.
Nutra Pharma Announces the Submission of Their First Orphan Drug Application to the US Food and Drug Administration (FDA)
Marketwired - Wed Jul 15, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have filed an application with the FDA for orphan drug status of the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children.
SeeThruEquity Initiates Coverage on Nutra Pharma Corporation with a Price Target of $0.53
ACCESSWIRE - Fri Jul 10, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / July 10, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nutra Pharma Corporation (OTC: NPHC) with a Price Target of $0.53.
Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services
Marketwired - Tue Jun 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Pickwick will focus on assisting Nutra Pharma in its strategies for maximizing shareholder value through its full scope of investment banking services.
Nutra Pharma enters into facility and personnel sharing agreement with Nationwide Laboratory Services
M2 - Wed Jun 10, 3:23AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) revealed on Tuesday the execution of a facility and personnel sharing agreement with Nationwide Laboratory Services.
Nutra Pharma Announces Collaboration With Nationwide Laboratories
Marketwired - Tue Jun 09, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc.
Nutra Pharma Announces Orphan Drug Applications for RPI-78M
Marketwired - Tue May 26, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Medical Strategy Consultants, LLC to aid the company in the filing of Orphan Drug applications with the U.S. Food and Drug Administration ("FDA" . The first application under development is for the treatment of Pediatric Multiple Sclerosis with the Company's lead drug candidate, RPI-78M.
Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
Marketwired - Thu May 14, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Nature's Clinic to begin the process of regulatory approval of the Company's Over-the-Counter pain drug, Nyloxin(R) for marketing and distribution in Canada.
Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
Marketwired - Thu Apr 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have received notification of the acceptance of Nyloxin(R) by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
Marketwired - Wed Apr 22, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
Marketwired - Wed Apr 15, 7:30AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing an update regarding their plan to market their over-the-counter (OTC) pain reliever, Nyloxin(R) through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma previously announced that they had shipped their initial test orders of Nyloxin(R) in February to ensure Customs clearance before escalating order sizes and frequency. Nutra Pharma management has been working in Mumbai this week to finalize their plans for the national rollout of Nyloxin.
Nutra Pharma Announces Distribution of Nyloxin(R) to India
Marketwired - Thu Feb 05, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have shipped their initial test orders of their Over-the-Counter pain drug, Nyloxin(R), to S.Zhaveri Pharmakem for distribution throughout India.
Nutra Pharma Letter to Shareholders
Marketwired - Wed Dec 30, 7:30AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, has published a Shareholder Letter on the Company's website.
Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview
Marketwired - Wed Dec 16, 7:30AM CST
QualityStocks today announces the availability of a new audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTCQB: NPHC), a biotech company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The interview can be heard at http://www.QualityStocks.net/interview-nphc.php.
Nutra Pharma Corp. (NPHC) Announces Engagement of QualityStocks Corporate Communications Suite
Marketwired - Mon Dec 14, 7:30AM CST
Nutra Pharma Corp. (the "Company"
(OTCQB: NPHC), a biopharmaceutical company engaged in the acquisition, licensing and marketing of homeopathic treatments and ethical drugs for the management of pain, neurological disorders, cancer, auto-immune and infectious diseases, today announces that it has engaged the Corporate Communications Services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value over the past 9 years and 11 months. Nutra Pharma files for additional orphan drug application with the US FDA for RPI-78M for Myasthenia Gravis
M2 - Thu Dec 10, 5:02AM CST
Biotechnology company Nutra Pharma Corporation (OTCQB:NPHC) disclosed on Wednesday that it has applied for an additional potential orphan drug designation with the US-FDA for its RPI-78M drug candidate for the treatment of Myasthenia Gravis (MG) through the modulation of the immune system, preventing autoimmune effects.
Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis
Marketwired - Wed Dec 09, 8:02AM CST
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, as well as developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have applied for an Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Myasthenia Gravis (MG). On September 8, 2015, the Company announced that they had been granted an Orphan Designation for the treatment of Pediatric Multiple Sclerosis. The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.
StockNewsNow.com Publishes New SNNLive Video Interview With Nutra Pharma Corporation
Marketwired - Tue Oct 27, 7:31AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an SNNLive Video Interview with Rik J. Deitsch, CEO of Nutra Pharma Corporation (OTC: NPHC), operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, (see here: www.NutraPharma.com). The video interview was recorded on Wednesday, October 14th, 2015 On-Location in Florida.
Nutra Pharma to Present at Upcoming Investment Conference
Marketwired - Wed Sep 09, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, will be presenting at the upcoming See Thru Equities Conference being held at the Convene Grand Central in New York City on Thursday, September 10th. The presentation will be made by the Company's CEO, Rik J Deitsch, who will be providing updates on the sales and marketing activities for the Company's over-the-counter (OTC) pain relievers, Nyloxin(R) and Pet Pain-Away, as well as discussing the Company's drug product pipeline. This will include a presentation on the designation of Orphan Drug Status for RPI-78M in the treatment of juvenile Multiple Sclerosis (MS).
Nutra Pharma wins US FDA's orphan drug status for RPI-78M for treating juvenile multiple sclerosis
M2 - Wed Sep 09, 3:27AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) reported on Tuesday ththat it has been given orphan drug designation from the US-FDA for its RPI-78M drug candidate for treating multiple sclerosis in children.
Nutra Pharma's RPI-78M Granted Orphan Drug Status by the US Food and Drug Administration for the Treatment of Juvenile Multiple Sclerosis
Marketwired - Tue Sep 08, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC) announced today that they have received Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children.
Nutra Pharma Announces the Submission of Their First Orphan Drug Application to the US Food and Drug Administration (FDA)
Marketwired - Wed Jul 15, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have filed an application with the FDA for orphan drug status of the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children.
SeeThruEquity Initiates Coverage on Nutra Pharma Corporation with a Price Target of $0.53
ACCESSWIRE - Fri Jul 10, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / July 10, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Nutra Pharma Corporation (OTC: NPHC) with a Price Target of $0.53.
Nutra Pharma Announces Engagement of Investment Banking Firm Pickwick Capital Partners to Provide Strategic Advisory Services
Marketwired - Tue Jun 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin(R) and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Pickwick Capital Partners; a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services. Pickwick will focus on assisting Nutra Pharma in its strategies for maximizing shareholder value through its full scope of investment banking services.
Nutra Pharma enters into facility and personnel sharing agreement with Nationwide Laboratory Services
M2 - Wed Jun 10, 3:23AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) revealed on Tuesday the execution of a facility and personnel sharing agreement with Nationwide Laboratory Services.
Nutra Pharma Announces Collaboration With Nationwide Laboratories
Marketwired - Tue Jun 09, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have entered into a facility and personnel sharing agreement with Nationwide Laboratory Services, Inc.
Nutra Pharma Announces Orphan Drug Applications for RPI-78M
Marketwired - Tue May 26, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged Medical Strategy Consultants, LLC to aid the company in the filing of Orphan Drug applications with the U.S. Food and Drug Administration ("FDA"
. The first application under development is for the treatment of Pediatric Multiple Sclerosis with the Company's lead drug candidate, RPI-78M. Nutra Pharma Announces Nyloxin(R) Distribution Plans for Canada
Marketwired - Thu May 14, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Nature's Clinic to begin the process of regulatory approval of the Company's Over-the-Counter pain drug, Nyloxin(R) for marketing and distribution in Canada.
Nutra Pharma Announces Nyloxin(R) Acceptance by Chinese Medical Authority - CPAM
Marketwired - Thu Apr 30, 7:30AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have received notification of the acceptance of Nyloxin(R) by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM). This process was successfully conducted by the Vancouver Commodities Group (VCG) that had been hired by Nutra Pharma to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Announces Nyloxin(R) Distribution Plans for China
Marketwired - Wed Apr 22, 7:31AM CDT
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have engaged the Vancouver Commodities Group (VCG) to begin the process of identifying and vetting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin(R).
Nutra Pharma Provides Updates on Marketing and Distribution of Nyloxin(R) to India
Marketwired - Wed Apr 15, 7:30AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing an update regarding their plan to market their over-the-counter (OTC) pain reliever, Nyloxin(R) through S.Zhaveri Pharmakem for distribution throughout India. Nutra Pharma previously announced that they had shipped their initial test orders of Nyloxin(R) in February to ensure Customs clearance before escalating order sizes and frequency. Nutra Pharma management has been working in Mumbai this week to finalize their plans for the national rollout of Nyloxin.
Nutra Pharma Announces Distribution of Nyloxin(R) to India
Marketwired - Thu Feb 05, 7:30AM CST
Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have shipped their initial test orders of their Over-the-Counter pain drug, Nyloxin(R), to S.Zhaveri Pharmakem for distribution throughout India.
